MARK4

Across TCGA pan-cancer cohorts, MARK4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MARK4 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MARK4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MARK4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

LUAD, UCEC, and SCLC are the cancer types where MARK4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.265	0.837	<.001	34	view →
UCEC	DFS	Median	All	0.956	0.623	.022	6	view →
SCLC	DFS	Median	All	1.000	0.591	.019	5	view →
LIHC	OS	Median	All	0.105	0.774	.002	5	view →
SKCM	OS	Median	III,IV	0.230	0.721	.021	3	view →
COAD	DFS	Median	II,III,IV	1.000	0.746	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MARK4–LUAD (OS)

Open the LUAD breakdown →